Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Andrew Elliott

Showing results (121-130 of 157) with videos related to

Pageof 16
Sort By:
Frontiers in Oncology|May 11, 2023
<i>ERBB</i> family fusions are recurrent and actionable oncogenic targets across cancer typesLaura Schubert, Andrew Elliott, Anh T Le, et al.
Nature|September 17, 2025
Basal cell of origin resolves neuroendocrine-tuft lineage plasticity in cancerAbbie S Ireland, Daniel A Xie, Sarah B Hawgood, et al.
International Journal of Molecular Sciences|June 26, 2025
<i>HSD3B1</i> (c.1100C) Genotype Is Associated with Distinct Tumoral and Clinical Outcomes in Breast and Endometrial CancersNikitha Vobugari, Allison Makovec, Samuel Kellen, et al.
The Journal of Clinical Investigation|April 23, 2024
Renal cell carcinoma histologic subtypes exhibit distinct transcriptional profilesPedro Barata, Shuchi Gulati, Andrew Elliott, et al.
ESMO Open|November 24, 2020
Molecular characteristics of <i>BRCA1/2</i> and <i>PALB2</i> mutations in pancreatic ductal adenocarcinomaAndreas Seeber, Kai Zimmer, Florian Kocher, et al.
NPJ Precision Oncology|May 6, 2024
Author Correction: Mutational signature-based identification of DNA repair deficient gastroesophageal adenocarcinomas for therapeutic targetingAurel Prosz, Pranshu Sahgal, Brandon M Huffman, et al.
NPJ Precision Oncology|April 8, 2024
Mutational signature-based identification of DNA repair deficient gastroesophageal adenocarcinomas for therapeutic targetingAurel Prosz, Pranshu Sahgal, Brandon M Huffman, et al.
Cancer Research Communications|January 28, 2025
Expression Patterns of DLL3 across Neuroendocrine and Non-neuroendocrine Neoplasms Reveal Broad Opportunities for Therapeutic TargetingJohn R Lozada, Andrew Elliott, Mark G Evans, et al.
Cancers|October 13, 2021
Genomic Landscape of Angiosarcoma: A Targeted and Immunotherapy Biomarker AnalysisAndrea P Espejo-Freire, Andrew Elliott, Andrew Rosenberg, et al.
British Journal of Cancer|June 6, 2022
Benefit from upfront FOLFOXIRI and bevacizumab in BRAFV600E-mutated metastatic colorectal cancer patients: does primary tumour location matter?Roberto Moretto, Andrew Elliott, Daniele Rossini, et al.
Pageof 16

Showing results (121-130 of 157) with videos related to

Sort By:
Pageof 16
Frontiers in Oncology|May 11, 2023
<i>ERBB</i> family fusions are recurrent and actionable oncogenic targets across cancer typesLaura Schubert, Andrew Elliott, Anh T Le, et al.
Nature|September 17, 2025
Basal cell of origin resolves neuroendocrine-tuft lineage plasticity in cancerAbbie S Ireland, Daniel A Xie, Sarah B Hawgood, et al.
International Journal of Molecular Sciences|June 26, 2025
<i>HSD3B1</i> (c.1100C) Genotype Is Associated with Distinct Tumoral and Clinical Outcomes in Breast and Endometrial CancersNikitha Vobugari, Allison Makovec, Samuel Kellen, et al.
The Journal of Clinical Investigation|April 23, 2024
Renal cell carcinoma histologic subtypes exhibit distinct transcriptional profilesPedro Barata, Shuchi Gulati, Andrew Elliott, et al.
ESMO Open|November 24, 2020
Molecular characteristics of <i>BRCA1/2</i> and <i>PALB2</i> mutations in pancreatic ductal adenocarcinomaAndreas Seeber, Kai Zimmer, Florian Kocher, et al.
NPJ Precision Oncology|May 6, 2024
Author Correction: Mutational signature-based identification of DNA repair deficient gastroesophageal adenocarcinomas for therapeutic targetingAurel Prosz, Pranshu Sahgal, Brandon M Huffman, et al.
NPJ Precision Oncology|April 8, 2024
Mutational signature-based identification of DNA repair deficient gastroesophageal adenocarcinomas for therapeutic targetingAurel Prosz, Pranshu Sahgal, Brandon M Huffman, et al.
Cancer Research Communications|January 28, 2025
Expression Patterns of DLL3 across Neuroendocrine and Non-neuroendocrine Neoplasms Reveal Broad Opportunities for Therapeutic TargetingJohn R Lozada, Andrew Elliott, Mark G Evans, et al.
Cancers|October 13, 2021
Genomic Landscape of Angiosarcoma: A Targeted and Immunotherapy Biomarker AnalysisAndrea P Espejo-Freire, Andrew Elliott, Andrew Rosenberg, et al.
British Journal of Cancer|June 6, 2022
Benefit from upfront FOLFOXIRI and bevacizumab in BRAFV600E-mutated metastatic colorectal cancer patients: does primary tumour location matter?Roberto Moretto, Andrew Elliott, Daniele Rossini, et al.
Pageof 16